MP46-18 USE OF ABIRATERONE ACETATE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST EFFECTIVENESS STUDY

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Value of Care: Cost and Outcomes Measures II1 Apr 2016MP46-18 USE OF ABIRATERONE ACETATE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST EFFECTIVENESS STUDY Dragomir Alice, Joice Rocha, Armen Aprikian, Marie Vanhuyse, Fabio Cury, and Wassim Kassouf Dragomir AliceDragomir Alice More articles by this author , Joice RochaJoice Rocha More articles by this author , Armen AprikianArmen Aprikian More articles by this author , Marie VanhuyseMarie Vanhuyse More articles by this author , Fabio CuryFabio Cury More articles by this author , and Wassim KassoufWassim Kassouf More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.316AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Abiraterone was introduced in Quebec in 2012 for the management of metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting. This study evaluated the cost-effectiveness of abiraterone in the management of mCRPC in a real-life setting in Quebec. METHODS A retrospective cohort study was conducted using Quebec public healthcare administrative databases. Our cohort consisted of mCRPC patients receiving chemotherapy (docetaxel) from 2009-2010 (N=191), and abiraterone treatments from 2012-2013 (N=303; defined as abiraterone overall). The abiraterone group was stratified into abiraterone post-chemotherapy (N=99) and abiraterone without prior chemotherapy (N=204). Survival was evaluated comparing abiraterone groups to the chemotherapy group. Incremental cost-effectiveness ratio (ICER) was obtained by dividing changes in primary therapy costs and survival in the two periods. RESULTS A 2- and 5-month survival increment was seen in the abiraterone overall (P=0.021; hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.64-1.1) and the abiraterone post-chemotherapy groups (P=0.0048; HR 0.68, 95%CI 0.47-0.98) when compared to the chemotherapy group. Yet no difference in survival was found in the abiraterone without prior chemotherapy group compared to the chemotherapy group. Total mCRPC medication costs were on average $11,541 for the chemotherapy group, and approximately $30,000 in the abiraterone groups. The ICER per life year gained was $69,627 for the abiraterone post-chemotherapy group, and $117,140 for the abiraterone overall group. CONCLUSIONS Our real-life study indicates that patients receiving abiraterone overall or in the post-chemotherapy setting had a survival benefit when compared to the group receiving only chemotherapy. Addition of abiraterone was associated with an important ICER, which was increased in the abiraterone overall group due to the reduced efficacy found in patients receiving abiraterone without prior docetaxel. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e624 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Dragomir Alice More articles by this author Joice Rocha More articles by this author Armen Aprikian More articles by this author Marie Vanhuyse More articles by this author Fabio Cury More articles by this author Wassim Kassouf More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...